Skip to content

Trial Summary

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

Acronym:

GO40558

ACTRN/NCT /ethics:

NCT03815058

Scientific title:

A study to evaluate the efficacy and safety of RO7198457 in combination with pembrolizumab versus pembrolizumab alone in participants with previously untreated advanced melanoma.

Sponsor / Cooperative group:

Genentech Inc.

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream Advanced melanoma
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2019-01-08
Anticipated End Date2022-09-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusRecruiting